Assessing Lead Time Of Selected Ovarian Cancer Biomarkers
Links shared publicly online about this topic.
- 1,492total visits
Assessing Lead Time Of Selected Ovarian Cancer Biomarkers
Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published onlin
View full resource at medicalnewstoday.com
Tags: Cancer, Ovarian Cancer, Protein, Women's Health
Most Recently Shared on December 31, 2009 at 2:04 am By:
Assessing Lead Time Of Selected Ovarian Cancer Biomarkers http://mnt.to/3vQN
Also Shared By:
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al. 102 (1): 26 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al. 102 (1): 26 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on December 30, 2009 at 9:20 pm By:
J Nat'l Cancer Inst Medical Journal and Oncology
Ovarian cancr screening: biomarker conc. rose 3 years before diagnosis—only became markedly elevated in last yr, though http://bit.ly/6BGSMg
Advertisement
MNT Cancer News
@mnt_cancer
Assessing Lead Time Of Selected Ovarian Cancer Biomarkers http://mnt.to/3vQN
1 year ago...